AntiTNF trough levels
| Trough drug level (μg/ml) | Infliximab | Adalimumab |
|---|---|---|
| Low (<2 IFX, <5 ADA) | 34% | 41% |
| Therapeutic (2–8 IFX, 5–8 ADA) | 54% | 44% |
| High (>8) | 12% | 15% |
46% patients on IFX and 56% patients on ADA had drug levels outside the ideal therapeutic window (Table 1).